These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1246 related items for PubMed ID: 15500434

  • 1. AT1 receptor blockade for the prevention of cardiovascular events after myocardial infarction.
    Azadpour M, Lamas GA.
    Expert Rev Cardiovasc Ther; 2004 Nov; 2(6):891-902. PubMed ID: 15500434
    [Abstract] [Full Text] [Related]

  • 2. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [Abstract] [Full Text] [Related]

  • 3. Comparison between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: a meta-analysis.
    Reboldi G, Angeli F, Cavallini C, Gentile G, Mancia G, Verdecchia P.
    J Hypertens; 2008 Jul; 26(7):1282-9. PubMed ID: 18550998
    [Abstract] [Full Text] [Related]

  • 4. The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
    McMurray J, Solomon S, Pieper K, Reed S, Rouleau J, Velazquez E, White H, Howlett J, Swedberg K, Maggioni A, Køber L, Van de Werf F, Califf R, Pfeffer M.
    J Am Coll Cardiol; 2006 Feb 21; 47(4):726-33. PubMed ID: 16487836
    [Abstract] [Full Text] [Related]

  • 5. Treatments that improve outcome in the patient with heart failure, left ventricular systolic dysfunction, or both after acute myocardial infarction.
    Weir R, McMurray JJ.
    Heart; 2005 May 21; 91 Suppl 2(Suppl 2):ii17-20; discussion ii31, ii43-8. PubMed ID: 15831602
    [Abstract] [Full Text] [Related]

  • 6. Usefulness of beta blockers in high-risk patients after myocardial infarction in conjunction with captopril and/or valsartan (from the VALsartan In Acute Myocardial Infarction [VALIANT] trial).
    Califf RM, Lokhnygina Y, Velazquez EJ, McMurray JJ, Leimberger JD, Lewis EF, Diaz R, Murin J, Pfeffer MA.
    Am J Cardiol; 2009 Jul 15; 104(2):151-7. PubMed ID: 19576338
    [Abstract] [Full Text] [Related]

  • 7. Improving outcomes in post-acute myocardial infarction heart failure: incorporation of aldosterone blockade into combination therapy to optimize neurohormonal blockade.
    Pitt B, Fonarow GC, Gheorghiade M, Deedwania PC, Duprez DA.
    Am J Cardiol; 2006 May 22; 97(10A):26F-33F. PubMed ID: 16698332
    [Abstract] [Full Text] [Related]

  • 8. [Effect of combined beta-blocker and angiotensin-converting enzyme inhibitor treatment on 1-year survival after acute myocardial infarction: findings of the PRIAMHO-II registry].
    Arós F, Loma-Osorio A, Vila J, López-Bescós L, Cuñat J, Rodríguez E, San José JM, Heras M, Marrugat J, Investigadores del PRIAMHO II.
    Rev Esp Cardiol; 2006 Apr 22; 59(4):313-20. PubMed ID: 16709383
    [Abstract] [Full Text] [Related]

  • 9. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR.
    Clin Ther; 2007 Sep 22; 29(9):1803-24. PubMed ID: 18035185
    [Abstract] [Full Text] [Related]

  • 10. Which inhibitor of the renin-angiotensin system should be used in chronic heart failure and acute myocardial infarction?
    McMurray JJ, Pfeffer MA, Swedberg K, Dzau VJ.
    Circulation; 2004 Nov 16; 110(20):3281-8. PubMed ID: 15545527
    [No Abstract] [Full Text] [Related]

  • 11. [ACE inhibitors and angiotensin II receptor antagonists in acute coronary syndrome].
    Milicić D.
    Acta Med Croatica; 2004 Nov 16; 58(2):129-34. PubMed ID: 15208798
    [Abstract] [Full Text] [Related]

  • 12. Dual renin angiotensin system blockade in patients with acute myocardial infarction and preserved left ventricular systolic function.
    Suşan M, Petrescu L, Riviş AI, Suşan RM, Burghină D, Dan R, Cozma D, Drăgulescu SI.
    Rom J Intern Med; 2005 Nov 16; 43(3-4):187-98. PubMed ID: 16812979
    [Abstract] [Full Text] [Related]

  • 13. Blocking the renin-angiotensin system: dual- versus mono-therapy.
    Ravandi A, Teo KK.
    Expert Rev Cardiovasc Ther; 2009 Jun 16; 7(6):667-74. PubMed ID: 19505282
    [Abstract] [Full Text] [Related]

  • 14. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker.
    Furumatsu Y, Nagasawa Y, Tomida K, Mikami S, Kaneko T, Okada N, Tsubakihara Y, Imai E, Shoji T.
    Hypertens Res; 2008 Jan 16; 31(1):59-67. PubMed ID: 18360019
    [Abstract] [Full Text] [Related]

  • 15. [Treatment of heart failure based on large-scale clinical trials: renin-angiotensin system antagonists and beta-blockers].
    Kubota T, Takeshita A.
    Nihon Rinsho; 2003 May 16; 61(5):801-6. PubMed ID: 12755006
    [Abstract] [Full Text] [Related]

  • 16. Inhibition of the renin-angiotensin-aldosterone system to prevent ischemic and atherothrombotic events.
    Papademetriou V.
    Am Heart J; 2009 Jun 16; 157(6 Suppl):S24-30. PubMed ID: 19450721
    [Abstract] [Full Text] [Related]

  • 17. Role of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and aldosterone antagonists in the prevention of atrial and ventricular arrhythmias.
    Makkar KM, Sanoski CA, Spinler SA.
    Pharmacotherapy; 2009 Jan 16; 29(1):31-48. PubMed ID: 19113795
    [Abstract] [Full Text] [Related]

  • 18. Current possibilities of ACE inhibitor and ARB combination in arterial hypertension and its complications.
    Kolasinska-Malkowska K, Filipiak KJ, Gwizdala A, Tykarski A.
    Expert Rev Cardiovasc Ther; 2008 Jun 16; 6(5):759-71. PubMed ID: 18510491
    [Abstract] [Full Text] [Related]

  • 19. Aldosterone receptor antagonism and heart failure: insights from an outpatient clinic.
    Mariotti R, Borelli G, Coceani M, Zingaro S, Barison A, Morelli I, Rondinini L.
    J Clin Pharm Ther; 2008 Aug 16; 33(4):349-56. PubMed ID: 18613852
    [Abstract] [Full Text] [Related]

  • 20. Inhibiting the renin-angiotensin system in myocardial infarction and heart failure: lessons from SAVE, VALIANT and CHARM, and other clinical trials.
    Tokmakova M, Solomon SD.
    Curr Opin Cardiol; 2006 Jul 16; 21(4):268-72. PubMed ID: 16755193
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 63.